Certa have developed a series of small molecule inhibitors of GPR68 with the aim of tackling fibrotic diseases upstream of other targeted biological pathways.
Certa has now brought together a consolidated portfolio of specific molecules which all target GPR68. They have been designed with characteristics to safely and effectively address different fibrotic conditions.
Fibrotic diseases are an area of significant unmet need, responsible for an estimated 35.4% of all deaths globally.
Certa’s lead programme, FT011 (asengeprast), is being developed as a novel, first-in-class oral therapy for the treatment of systemic sclerosis (scleroderma) and has successfully completed a multi-national, phase II clinical trial. It has been awarded Orphan Drug Designation by the FDA and EMA for the treatment of scleroderma.
Further programs address major indications including chronic kidney disease, diabetic nephropathy and other chronic fibrotic indications.
